Movement Alert|Ionis Pharmaceuticals Falls 5.11% in Regular Trading, EU Tryngolza Expansion Fails to Offset Commercialization Concerns

Market Focus04:01

On November 18, Ionis Pharmaceuticals fell 5.11% in Regular Trading to $26.58 per share, with turnover of $52.2608 million.

The latest catalyst was the European Commission approval of Tryngolza for adults with severe hypertriglyceridemia, expanding beyond its prior EU approval in familial chylomicronemia syndrome. The drug had met the primary endpoint in two phase 3 trials, lowering triglycerides and reducing acute pancreatitis events versus placebo, while Sobi holds exclusive commercialization rights outside the US except Canada and China.

Even so, the market remained focused on commercialization pressure after Ionis previously cut full-year Tryngolza sales guidance to $50 million from $100 million to $110 million. That overhang persisted despite third-quarter revenue rising 55% year over year to $243 million and net loss narrowing to $0.66 per share, both better than consensus expectations, while the company maintained total revenue guidance of $875 million to $900 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment